Skip Nav Destination
Issues
1 January 2024
-
Cover Image
Cover Image
The cover image is adapted from Fig. 3 in the article, “Investigating Causal Effects of Hematological Traits on Lung Cancer: A Mendelian Randomization Study,” by Yang and colleagues. Figure 3 shows scatter plots for three identified hematological traits and lung carcinoma. Observational studies have suggested blood cell counts may act as predictors of cancer. It is not known whether these hematological traits are causally associated with lung cancer. In this study, using summary data of large-scale GWAS, the authors performed a series of two-sample MR analyses to establish whether hematological traits have a causal effect on the risk of lung cancer and its different subtypes. They found evidence that genetically influenced higher hematocrit and hemoglobin concentration and reticulocyte count decreased lung carcinoma risk, especially in ever smokers. Multivariable MR (MVMR) further identified hematocrit independently of smoking as an independent predictor. Subgroup analysis showed that a higher plateletcrit level increased the risk of small cell lung carcinoma. Hematological traits may act as low-cost factors for lung cancer risk stratification. Further studies are required to elucidate the potential mechanisms underlying the dysregulation of homeostasis related to hematological traits, such as subclinical inflammation. For more information, see the article beginning on page 96. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1055-9965
EISSN 1538-7755
Issue Sections
Highlights
Obituary
Minireview
Review
Research Articles
Adherence to 2018 WCRF/AICR Cancer Prevention Recommendations and Risk of Cancer: The Melbourne Collaborative Cohort Study
Yang Peng; Julie K. Bassett; Allison M. Hodge; Yohannes Adama Melaku; Nina Afshar; John L. Hopper; Robert J. MacInnis; Brigid M. Lynch; Stephanie A. Smith-Warner; Graham G. Giles; Roger L. Milne; Harindra Jayasekara
Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
David L. Ashley; Wanzhe Zhu; Deepak Bhandari; Lanqing Wang; Jun Feng; Yuesong Wang; Lei Meng; Baoyun Xia; Jeffery M. Jarrett; Cindy M. Chang; Heather L. Kimmel; Benjamin C. Blount
A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Michael K. Odutola; Marina T. van Leeuwen; Fiona Bruinsma; Jennifer Turner; Mark Hertzberg; John F. Seymour; H. Miles Prince; Judith Trotman; Emma Verner; Fernando Roncolato; Stephen Opat; Robert Lindeman; Campbell Tiley; Samuel T. Milliken; Craig R. Underhill; Geza Benke; Graham G. Giles; Claire M. Vajdic
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.